JUN 27, 2018 12:00 AM PDT

Engineered Poliovirus in Clinical Trials for Glioblastoma

WRITTEN BY: Mauri Brueggeman

Phase I clinical trial study results published June 26, 2018 in The New England Journal of Medicine outline how researchers used a novel recombinant poliovirus to treat glioblastoma. 

Recurrent malignant glioma, or glioblastoma, at a late stage (World Health Organization grade IV), has a very poor prognosis.  There is no currently accepted effective therapy and this type of malignancy is being seen more and more in the world.  Treatments historically included surgical removal, radiotherapy, chemotherapy, and targeted therapies but have resulted in inconsistent results along with challenging central nervous system side effects. 

The poliovirus is one of a small number of viruses known to infect and be brought into nerve cells.  Once inside the cell, the virus, like other viral mechanisms of action, commandeers the cell’s replication assembly process to make copies of itself in a short span of time.  Once replication is complete, the virus destroys the cell and goes on to infect other nerve cells.  The reason this particular virus utilizes motor neurons, rather than other cell types, is still unknown.

In this study, the researchers engineered the poliovirus type 1 to include a ribosome entry site from a human rhinovirus type 2, to replace its original entry site (PVSRIPO).  This non-native ribosome entry site does not allow the virus to recruit the cellular machinery required to translate the viral genome and further infect other neurons.  Instead, the engineered virus has affinity for cluster of differentiation 155 (CD155), which is present on malignant cells.  The infected glioma cells are destroyed, and the innate antiviral immune response ensues. 

Results of this initial phase were promising.  Overall survival rate for those treated with PVSRIPO was 21% at 24 and 36 months; the historical control overall survival rate was 14% at 24 months and 4% at 36 months.  In a dose-expansion phase, some patients showed neurological side effects which the researchers speculated to be a result of treatment related peritumoral edema and were swiftly treated with bevacizumab to reduce edema and mitigate symptoms. 

This group currently has a phase 2, randomized clinical trial underway using PVSRIPO in WHO grade IV glioblastoma.

Sources: New England Journal of Medicine, Smithsonian, ClinicalTrials.gov Phase I, ClinicalTrials.gov Phase II,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
APR 05, 2021
Cancer
Introducing DeepTCR, the deep-learning software for T-cell receptor sequencing data
APR 05, 2021
Introducing DeepTCR, the deep-learning software for T-cell receptor sequencing data
A team from the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center is introdu ...
APR 04, 2021
Drug Discovery & Development
Ion-Pump for Chemotherapy
APR 04, 2021
Ion-Pump for Chemotherapy
Patients of malignant brain tumors experience recurrences even after subsequent treatments. To address this issue, scien ...
APR 19, 2021
Cancer
Understanding why pacreatic cancer metastasizes
APR 19, 2021
Understanding why pacreatic cancer metastasizes
New research published in the journal Gastroenterology reports on the mechanisms of metastatic pancreatic cancer cells, ...
MAY 19, 2021
Cancer
How does environmental quality affect prostate cancer aggressiveness?
MAY 19, 2021
How does environmental quality affect prostate cancer aggressiveness?
A study from researchers at the University of Illinois Chicago investigates the link between environmental quality and p ...
MAY 27, 2021
Cancer
Which ovarian cancer patients will be resistant to platinum chemotherapy?
MAY 27, 2021
Which ovarian cancer patients will be resistant to platinum chemotherapy?
Research published in the journal EMBO Molecular Medicine details a novel mechanism that can be used to predict which ep ...
MAY 27, 2021
Microbiology
Some Microbes May Protect the Gut From Chemo's Harmful Effects
MAY 27, 2021
Some Microbes May Protect the Gut From Chemo's Harmful Effects
The microbes in our gut can influence our physiology in many ways. Some gut microbes have a positive impact on human hea ...
Loading Comments...